Levitra, UroXatral Clear Safety Hurdle; Labels Should Describe QT Effect

Labeling for Bayer/GlaxoSmithKline's erectile dysfunction therapy Levitra and Sanofi-Synthelabo's UroXatral for benign prostatic hyperplasia should include some discussion of the drugs' effects on the QT interval, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said at its May 29 meeting